Nyxoah SA may now help make dreams come true here in the U.S. with its FDA approval for the Genio system for the treatment of obstructive sleep apnea.

Nyxoah SA recently raised $27 million after selling three million shares in a bid to shore up its capital base as it prepares to commercialize Genio — its obstructive sleep apnea technology — in the U.S.